Skip to main content

Artivion, Inc.

corporate_fare Company Profile

Artivion, Inc.

AORT·NYSE·Industrial Applications And Services·CIK 0000784199

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues for cardiac and vascular surgical procedures, specifically for patients with aortic disease. The company has four main product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts (such as E-vita Open NEO, E-vita Open Plus, Arcevo LSA Hybrid Stent Graft System, Ascyrus Medical Dissection Stent hybrid prosthesis, the NEXUS family of products including NEXUS ONE, NEXUS DUO, and NEXUS TRE, and E-vita Thoracic 3G products) and abdominal stent grafts (including E-xtra Design Engineering, E-nside, Artivex, E-tegra, E-ventus BX, Tuva BX, and E-liac products). Surgical sealants include BioGlue Surgical Adhesive products. Additionally, Artivion sells or distributes PhotoFix bovine surgical patches. The company began manufacturing and supplying PerClot hemostatic powder during the second quarter of 2023. Artivion operates through main subsidiaries including JOTEC GmbH, acquired on December 1, 2017, On-X Life Technologies, Inc., acquired on January 20, 2016, and Ascyrus Medical GmbH, acquired in September 2020, along with approximately twenty additional country entities for global sales and marketing. The company has two reportable segments: Medical Devices and Preservation Services.

Artivion, Inc. (NYSE:AORT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 14 items for AORT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for AORT spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • Artivion Q3: Revenue Up 9% to $123.8M, but Swings to $7.9M Net Loss
  • Q3 Revenue Up 9% but Adjusted EBITDA Falls 8% as Artivion Narrows Guidance
  • Artivion Q2 2026: Revenue Up 11% but Net Loss of $(13.5)M on Endospan Deal Costs and Contingent Consideration Charge
  • Artivion Q2 2026: Revenue Climbs 11%, but Acquisition Costs Deepen Net Loss; Guidance Holds Steady
  • FDA Approves Artivion's AMDS Hybrid Prosthesis for Acute Aortic Dissections, Targeting $150M Market

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$441.33M
Net Income
$9.77M
Diluted EPS
$0.21
Op. Cash Flow
$39.88M
Free Cash Flow
$839K
Gross Profit
$284.23M
Operating Income
$33.74M
Cash & Equivalents
$64.91M
Total Debt
$215.11M
Debt / Equity
0.48×
Net Margin
2.2%
Shares Outstanding
45.34M sh
Source: 10-K · filed 2026-02-18 · accession 0001628280-26-009046

Short Interest & Short Volume

7.22 days to cover

FINRA reported short interest of 3,412,435 shares in AORT as of the October 30, 2026 settlement, a 8.6% decrease from the prior period — about 7.2 days to cover at its recent average daily volume. On November 20, 2026, 60.2% of AORT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,412,435 shares as of October 30, 2026
Change vs prior period▼ 8.6%
Days to cover7.22 at avg daily volume of 472,904
Daily short volume (FINRA facilities)60.2% of 226,909 shares on November 20, 2026
5-day average short volume54.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$18.16
52-week range · as of 2026-11-06 $18.16 – $48.25
Market cap
$886.02M
Volume
642.1K (0.9× avg)
3-mo avg 740.5K
Live data · 2026-11-22 12:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AORT - Latest Insights

AORT
Nov 06, 2026, 12:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $20.66
Real-time Price: $18.16 info
Change: -$2.50 (-12%) info
Market Cap: $886.022M info
AORT
Nov 05, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $25.33
Real-time Price: $18.16 info
Change: -$7.17 (-28%) info
Market Cap: $886.022M info
AORT
Aug 07, 2026, 1:57 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $27.52
Real-time Price: $18.16 info
Change: -$9.36 (-34%) info
Market Cap: $886.022M info
AORT
Aug 06, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.77
Real-time Price: $18.16 info
Change: -$8.61 (-32%) info
Market Cap: $886.022M info
AORT
Jun 29, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $23.78
Real-time Price: $18.16 info
Change: -$5.62 (-24%) info
Market Cap: $886.022M info
AORT
May 18, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.54
Real-time Price: $18.16 info
Change: -$5.38 (-23%) info
Market Cap: $886.022M info
AORT
May 08, 2026, 10:56 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $25.55
Real-time Price: $18.16 info
Change: -$7.39 (-29%) info
Market Cap: $886.022M info
AORT
May 07, 2026, 6:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $27.98
Real-time Price: $18.16 info
Change: -$9.82 (-35%) info
Market Cap: $886.022M info
AORT
May 07, 2026, 4:43 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $24.40
Real-time Price: $18.16 info
Change: -$6.24 (-26%) info
Market Cap: $886.022M info
AORT
May 07, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.50
Real-time Price: $18.16 info
Change: -$7.34 (-29%) info
Market Cap: $886.022M info
AORT
Apr 07, 2026, 7:27 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $33.51
Real-time Price: $18.16 info
Change: -$15.35 (-46%) info
Market Cap: $886.022M info
AORT
Apr 01, 2026, 4:18 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $34.16
Real-time Price: $18.16 info
Change: -$16.00 (-47%) info
Market Cap: $886.022M info
AORT
Feb 18, 2026, 4:14 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $37.52
Real-time Price: $18.16 info
Change: -$19.36 (-52%) info
Market Cap: $886.022M info
AORT
Feb 12, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $38.82
Real-time Price: $18.16 info
Change: -$20.66 (-53%) info
Market Cap: $886.022M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets